In turn, PDL1 status is an important biomarker for immunotherapy in several cancer types, including lung cancer, where PDL1-positive staining of membranes of more than 50% of cancer cells serves as the key indication for prescription of PD1-specific immune check-point inhibitors, e.g., pembrolizumab, nivolumab, and atezolizumab [63]. This evidence concerns the gene CD274 and lung carcinoma.